Spartalizumab Triplet Does Not Improve PFS in Metastatic Melanoma

September 20, 2020

The phase 3 COMBI-I clinical trial of spartalizumab plus dabrafenib and trametinib showed no improvement in investigator-assessed progression-free survival in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, missing the primary end point in part 3 of the study.

PFS End Point Missed With Spartalizuamb, Dabrafenib, and Trametinib in Melanoma

September 19, 2020

The primary end point of investigator-assessed progression-free survival was missed in part 3 of the randomized, Phase 3 COMBI-i study of spartalizumab in combination with dabrafenib and trametinib in patients with untreated BRAF V600-mutant unresectable or metastatic melanoma, according to results presented at the 2020 ESMO Virtual Congress.

Sequencing Immunotherapy After Encorafenib and Binimetinib Showed Higher PFS in Metastatic Melanoma

September 19, 2020

The use of encorafenib and binimetinib followed by immunotherapy demonstrated a higher progression-free survival, as well as an objective response rate and median PFS at 1 and 2 years that were consistent with those reported in pivotal studies, according to a presentation by Paolo Ascierto, MD, at the 2020 ESMO Virtual Congress.

COMBI-i Regimen Does Not Improve PFS in Unresectable or Metastatic BRAF V600E-Mutant Melanoma

August 24, 2020

Progression-free survival was not improved with the combination of spartalizumab, dabrafenib, and trametinib when administered as treatment of untreated patients with unresectable or metastatic BRAF V600E-mutant cutaneous melanoma compared with dabrafenib plus trametinib alone, missing the primary end point of the phase 3 COMBI-I clinical trial.

First-Line Pembrolizumab Demonstrates Promising Activity in Phase 2 of Cutaneous Squamous Cell Carcinoma

August 07, 2020

Frontline treatment with the immune checkpoint inhibitor pembrolizumab as monotherapy generated promising activity against cutaneous squamous cell carcinoma with durable responses and a manageable safety profile.

Dendritic Cell Vaccine Shows Long-Term Survival Benefit in High-Risk Melanoma

August 06, 2020

The final data of a personalized tumor lysate, particle-loaded, dendritic cell vaccine demonstrated that patients with stage III or IV melanoma with high-risk of recurrence after complete surgical resection had better survival benefit and disease-free survival rate with the vaccine over placebo, according to a press release from Elios Therapeutics.

FDA Approves Atezolizumab Triplet Regimen for Treatment of Advanced BRAF-Mutant Melanoma

July 30, 2020

The FDA granted approval to atezolizumab in combination with cobimetinib and vemurafenib for the treatment of patients with BRAF V600E-mutated advanced melanoma.

FDA Grants Fast Track Designation to CMP-001 Combination in Advanced Melanoma

July 27, 2020

The FDA has granted Fast Track designation to CMP-001 in combination with nivolumab plus ipilimumab under 2 melanoma indications.

Chipping Away at the Surface of Melanoma Treatment: Narrowing Down Therapies

July 26, 2020

A guideline from the American Society of Clinical Oncology addresses 4 clinical questions regarding approaches to systemic treatment for different types and stages of melanoma, in addition to summarizing the trials on which the recommendations were based.

Tweet Chat Recap: Using Immunotherapy and Targeted Therapy for BRAF-Mutant Metastatic Melanoma

July 23, 2020

In an interview with Targeted Oncology, following the tweet chat, Shoushtari highlighted the key takeaways from the tweet chat discussion and spoke to how he would make his own treatment decisions for this patient scenario.